Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing
IMPORTANCE: In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physic...
Saved in:
| Published in | JAMA : the journal of the American Medical Association Vol. 317; no. 17; pp. 1785 - 1795 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Medical Association
02.05.2017
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | IMPORTANCE: In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing. OBJECTIVE: To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs. DESIGN, SETTING, AND PARTICIPANTS: The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy. EXPOSURES: Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians. MAIN OUTCOMES AND MEASURES: The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability. RESULTS: The analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, −2.18 to −1.18 percentage points; P < .001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P < .001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas. CONCLUSIONS AND RELEVANCE: Implementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies. |
|---|---|
| AbstractList | This study compares changes in physician prescribing patterns before and after implementation of policies at academic medical centers restricting on-site activities of pharmaceutical salespeople. IMPORTANCE: In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing. OBJECTIVE: To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs. DESIGN, SETTING, AND PARTICIPANTS: The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy. EXPOSURES: Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians. MAIN OUTCOMES AND MEASURES: The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability. RESULTS: The analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, −2.18 to −1.18 percentage points; P < .001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P < .001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas. CONCLUSIONS AND RELEVANCE: Implementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies. Importance In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing. Objective To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs. Design, Setting, and Participants The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy. Exposures Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians. Main Outcomes and Measures The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability. Results The analysis included 16?121?483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24?593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage points; P? In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing. To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs. The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy. Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians. The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability. The analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage points; P < .001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P < .001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas. Implementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies. In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing.IMPORTANCEIn an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative sales visits to physicians (known as detailing) between 2006 and 2012. Little is known about the effect of these policies on physician prescribing.To analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs.OBJECTIVETo analyze the association between detailing policies enacted at AMCs and physician prescribing of actively detailed and not detailed drugs.The study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy.DESIGN, SETTING, AND PARTICIPANTSThe study used a difference-in-differences multivariable regression analysis to compare changes in prescribing by physicians before and after implementation of detailing policies at AMCs in 5 states (California, Illinois, Massachusetts, Pennsylvania, and New York) that made up the intervention group with changes in prescribing by a matched control group of similar physicians not subject to a detailing policy.Academic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians.EXPOSURESAcademic medical center implementation of policies regulating pharmaceutical salesperson visits to attending physicians.The monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability.MAIN OUTCOMES AND MEASURESThe monthly within-drug class market share of prescriptions written by an individual physician for detailed and nondetailed drugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], attention-deficit/hyperactivity disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month period before implementation of the detailing policies with the 12- to 36-month period after implementation, depending on data availability.The analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage points; P < .001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P < .001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas.RESULTSThe analysis included 16 121 483 prescriptions written between January 2006 and June 2012 by 2126 attending physicians at the 19 intervention group AMCs and by 24 593 matched control group physicians. The sample mean market share at the physician-drug-month level for detailed and nondetailed drugs prior to enactment of policies was 19.3% and 14.2%, respectively. Exposure to an AMC detailing policy was associated with a decrease in the market share of detailed drugs of 1.67 percentage points (95% CI, -2.18 to -1.18 percentage points; P < .001) and an increase in the market share of nondetailed drugs of 0.84 percentage points (95% CI, 0.54 to 1.14 percentage points; P < .001). Associations were statistically significant for 6 of 8 study drug classes for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hyperactivity disorder drugs, and antidepressant drugs) and for 9 of the 19 AMCs that implemented policies. Eleven of the 19 AMCs regulated salesperson gifts to physicians, restricted salesperson access to facilities, and incorporated explicit enforcement mechanisms. For 8 of these 11 AMCs, there was a significant change in prescribing. In contrast, there was a significant change at only 1 of 8 AMCs that did not enact policies in all 3 areas.Implementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies.CONCLUSIONS AND RELEVANCEImplementation of policies at AMCs that restricted pharmaceutical detailing between 2006 and 2012 was associated with modest but significant reductions in prescribing of detailed drugs across 6 of 8 major drug classes; however, changes were not seen in all of the AMCs that enacted policies. |
| Author | Larkin, Ian Sah, Sunita Ang, Desmond Chao, Matthew Patterson, Mark Wu, Tina Loewenstein, George Hutchins, David Brennan, Troyen Steinhart, Jonathan Schoenbaum, Michael |
| AuthorAffiliation | 3 Austrian Institute of Technology, Seibersdorf, Austria 4 Johannes Kepler University, Linz, Austria 8 New York University Langone School of Medicine, New York, New York 6 Carnegie Mellon University, Pittsburgh, Pennsylvania 1 University of California, Los Angeles 5 Williams College, Williamstown, Massachusetts 7 Cornell University, Ithaca, New York 2 University of California, San Diego 10 CVS Caremark, Woonsocket, Rhode Island 9 National Institute of Mental Health, Bethesda, Maryland |
| AuthorAffiliation_xml | – name: 2 University of California, San Diego – name: 9 National Institute of Mental Health, Bethesda, Maryland – name: 3 Austrian Institute of Technology, Seibersdorf, Austria – name: 10 CVS Caremark, Woonsocket, Rhode Island – name: 4 Johannes Kepler University, Linz, Austria – name: 7 Cornell University, Ithaca, New York – name: 1 University of California, Los Angeles – name: 8 New York University Langone School of Medicine, New York, New York – name: 5 Williams College, Williamstown, Massachusetts – name: 6 Carnegie Mellon University, Pittsburgh, Pennsylvania |
| Author_xml | – sequence: 1 givenname: Ian surname: Larkin fullname: Larkin, Ian – sequence: 2 givenname: Desmond surname: Ang fullname: Ang, Desmond – sequence: 3 givenname: Jonathan surname: Steinhart fullname: Steinhart, Jonathan – sequence: 4 givenname: Matthew surname: Chao fullname: Chao, Matthew – sequence: 5 givenname: Mark surname: Patterson fullname: Patterson, Mark – sequence: 6 givenname: Sunita surname: Sah fullname: Sah, Sunita – sequence: 7 givenname: Tina surname: Wu fullname: Wu, Tina – sequence: 8 givenname: Michael surname: Schoenbaum fullname: Schoenbaum, Michael – sequence: 9 givenname: David surname: Hutchins fullname: Hutchins, David – sequence: 10 givenname: Troyen surname: Brennan fullname: Brennan, Troyen – sequence: 11 givenname: George surname: Loewenstein fullname: Loewenstein, George |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28464141$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1v1DAQxS1URLeFKwcOKBKXXrLYiR07F6Ttli-piD3A2ZrYs1uvErvYCaj_PU63rKASvlge_97ozbwzcuKDR0JeMrpklLK3exhgWVEml5zW7ROyYKJWZS1adUIWlLaqlFzxU3KW0p7mw2r5jJxWijeccbYgu1VKwTgYXfDFJY6_EH2xMmBxcKb4gtYZ6Is1-hFjsbmBOIDBabyvXuEIrnd-V2xC74zDVIC3mbpL-QW-2ERMJrouI8_J0y30CV883Ofk-4f339afyuuvHz-vV9cl8FqOpe2qCkAyI7eCQQOy66TaSkZb3loU3NiaCrSWC8MUMlXJViJwi23XyIbZ-py8O_S9nboBrcnGI_T6NroB4p0O4PS_P97d6F34qYViIm8nN7h4aBDDjwnTqAeXDPY9eAxT0kxlK0yKqs3om0foPkzR5_FmSkrVMsEz9fpvR0crfzLIwPIAmBhSirg9IozqOWQ9h6znkPUcchbwRwLjxvsE80Su_7_s1UE2l48umqpuqKx_A9ZXtVw |
| CitedBy_id | crossref_primary_10_17533_udea_iatreia_16 crossref_primary_10_2139_ssrn_4046264 crossref_primary_10_1177_07439156221098724 crossref_primary_10_2139_ssrn_3871392 crossref_primary_10_1001_jamanetworkopen_2018_6007 crossref_primary_10_1007_s40596_021_01401_6 crossref_primary_10_1016_j_jebo_2020_03_033 crossref_primary_10_1038_s41467_019_12317_z crossref_primary_10_1002_hec_4380 crossref_primary_10_1002_cpt_1074 crossref_primary_10_1257_app_20170647 crossref_primary_10_1007_s00134_018_5361_z crossref_primary_10_1016_j_obhdp_2019_03_005 crossref_primary_10_1177_10870547221099961 crossref_primary_10_2139_ssrn_3216172 crossref_primary_10_1007_s11257_021_09298_4 crossref_primary_10_1136_bmjqs_2022_014977 crossref_primary_10_2139_ssrn_3164259 crossref_primary_10_1016_j_obhdp_2019_07_005 crossref_primary_10_1093_eurpub_ckx204 crossref_primary_10_1007_s11606_022_07870_1 crossref_primary_10_1007_s40290_020_00341_0 crossref_primary_10_1377_hlthaff_2019_01289 crossref_primary_10_1080_15265161_2017_1329477 crossref_primary_10_1515_pubhef_2017_0029 crossref_primary_10_1016_j_jpubeco_2025_105311 crossref_primary_10_1093_haschl_qxad031 crossref_primary_10_2139_ssrn_4004107 crossref_primary_10_1016_j_jvir_2019_01_002 crossref_primary_10_1038_s41746_019_0142_9 crossref_primary_10_1177_10600280211033022 crossref_primary_10_1002_acn3_51326 crossref_primary_10_1108_JSM_08_2023_0301 crossref_primary_10_1371_journal_pone_0290603 crossref_primary_10_1016_j_ijrobp_2017_06_2445 crossref_primary_10_2139_ssrn_3786853 crossref_primary_10_3389_fpubh_2022_1072708 crossref_primary_10_1080_20479700_2020_1859757 crossref_primary_10_2139_ssrn_4082225 crossref_primary_10_1257_pol_20200044 crossref_primary_10_1177_01410768231181248 crossref_primary_10_1007_s10754_019_09265_y crossref_primary_10_1287_mnsc_2020_3940 crossref_primary_10_1017_S0140525X22002023 crossref_primary_10_1007_s11606_022_07457_w crossref_primary_10_1097_MNH_0000000000000861 crossref_primary_10_5465_amp_2021_0033 crossref_primary_10_1111_bdi_13114 crossref_primary_10_1007_s11606_019_05470_0 crossref_primary_10_1001_jamaophthalmol_2019_2456 crossref_primary_10_1007_s10805_017_9298_6 crossref_primary_10_1111_1475_6773_14024 crossref_primary_10_1001_jamaophthalmol_2019_0085 crossref_primary_10_1016_j_jvir_2020_02_014 crossref_primary_10_1136_bmjopen_2020_041098 crossref_primary_10_2139_ssrn_3446274 crossref_primary_10_1177_02761467211037323 crossref_primary_10_1016_j_jpubeco_2021_104402 crossref_primary_10_1177_237946151700300106 crossref_primary_10_1136_bmjgh_2024_016055 crossref_primary_10_1017_bpp_2023_37 crossref_primary_10_1002_arcp_1008 crossref_primary_10_2139_ssrn_3040045 crossref_primary_10_1377_hlthaff_2020_01785 crossref_primary_10_1542_peds_2022_056549 crossref_primary_10_1001_jamainternmed_2019_1196 crossref_primary_10_1164_rccm_201810_1865ST crossref_primary_10_2139_ssrn_4606312 crossref_primary_10_1108_IJPHM_05_2022_0043 crossref_primary_10_1016_S0140_6736_21_02252_2 crossref_primary_10_1001_jamainternmed_2018_4366 crossref_primary_10_1136_bmjebm_2020_111503 crossref_primary_10_1007_s11606_024_08668_z crossref_primary_10_1093_restud_rdae090 crossref_primary_10_2139_ssrn_4365190 |
| ContentType | Journal Article |
| Copyright | Copyright American Medical Association May 2, 2017 Copyright 2017 American Medical Association. All Rights Reserved. |
| Copyright_xml | – notice: Copyright American Medical Association May 2, 2017 – notice: Copyright 2017 American Medical Association. All Rights Reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7TQ 7TS 7U7 7U9 8FD C1K DHY DON FR3 H94 K9. M7N NAPCQ P64 RC3 7X8 5PM |
| DOI | 10.1001/jama.2017.4039 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts PAIS Index Physical Education Index Toxicology Abstracts Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management PAIS International PAIS International (Ovid) Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts Physical Education Index Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Nursing & Allied Health Premium Genetics Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) PAIS International AIDS and Cancer Research Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | Virology and AIDS Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Association Between Pharmaceutical Detailing Restrictions and Physician Prescribing |
| EISSN | 1538-3598 |
| EndPage | 1795 |
| ExternalDocumentID | PMC5815013 28464141 10_1001_jama_2017_4039 2623607 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: CVS Caremark – fundername: Division of Research and Faculty Development at Harvard Business School – fundername: National Science Foundation – fundername: National Institute of Mental Health |
| GroupedDBID | --- -ET -~X .55 .XZ 0R~ 0WA 186 18M 29J 2CT 2FS 2KS 2WC 354 39C 4.4 53G 5GY 5RE 6TJ 85S AAIKC AAMNW AAQOH AAQQT AAWTL ABBLC ABCQX ABEHJ ABIVO ABOCM ABPMR ABPPZ ABRSH ABWJO ACGFS ACNCT ACPRK ACQAM ADBBV ADUKH AETEA AFCHL AFFDN AFFNX AFRAH AGFXO AGHSJ AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BKOMP BRYMA C45 CJ0 CS3 EAM EBD EBS EJD EMOBN EX3 F5P GX1 HF~ KOO KQ8 L7B MVM N4W N9A NEJ NYF OBH OCB OGEVE OHH OK1 OMK OVD P2P PQQKQ QJJ RAJ RNS S10 SJN SV3 TEORI TN5 UHB UKR UPT VVN WH7 WOW X7M XHN XSW XZL YCJ YFH YOC YPV YQT YQY YR2 YSK YYM YZZ ZA5 ZCA ~H1 AAYXX ACAHW ADXHL ARBJA CITATION H13 YR5 CGR CUY CVF ECM EIF NPM UIG 7QL 7QP 7TK 7TQ 7TS 7U7 7U9 8FD C1K DHY DON FR3 H94 K9. M7N NAPCQ P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-a437t-db22aa71c7f51a6a7bb78f710949de54cd305edd45c18e182797ea4de9b6761d3 |
| ISSN | 0098-7484 1538-3598 |
| IngestDate | Thu Aug 21 18:24:54 EDT 2025 Fri Jul 11 02:19:17 EDT 2025 Fri Jul 25 20:43:02 EDT 2025 Thu Apr 03 06:55:56 EDT 2025 Tue Jul 01 01:54:32 EDT 2025 Thu Apr 24 23:01:20 EDT 2025 Fri Jul 05 02:04:15 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a437t-db22aa71c7f51a6a7bb78f710949de54cd305edd45c18e182797ea4de9b6761d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://doi.org/10.1001/jama.2017.4039 |
| PMID | 28464141 |
| PQID | 1897789154 |
| PQPubID | 42339 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5815013 proquest_miscellaneous_1894917529 proquest_journals_1897789154 pubmed_primary_28464141 crossref_primary_10_1001_jama_2017_4039 crossref_citationtrail_10_1001_jama_2017_4039 ama_primary_2623607 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-05-02 2017-May-02 20170502 |
| PublicationDateYYYYMMDD | 2017-05-02 |
| PublicationDate_xml | – month: 05 year: 2017 text: 2017-05-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Chicago |
| PublicationSubtitle | The Journal of the American Medical Association |
| PublicationTitle | JAMA : the journal of the American Medical Association |
| PublicationTitleAlternate | JAMA |
| PublicationYear | 2017 |
| Publisher | American Medical Association |
| Publisher_xml | – name: American Medical Association |
| References | 28464124 - JAMA. 2017 May 2;317(17 ):1772-1773 |
| References_xml | – reference: 28464124 - JAMA. 2017 May 2;317(17 ):1772-1773 |
| SSID | ssj0000137 |
| Score | 2.502495 |
| Snippet | IMPORTANCE: In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical... In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical representative... Importance In an effort to regulate physician conflicts of interest, some US academic medical centers (AMCs) enacted policies restricting pharmaceutical... This study compares changes in physician prescribing patterns before and after implementation of policies at academic medical centers restricting on-site... |
| SourceID | pubmedcentral proquest pubmed crossref ama |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1785 |
| SubjectTerms | Academic Medical Centers - statistics & numerical data Anticholesteremic Agents - therapeutic use Antidepressants Antidepressive Agents - therapeutic use Antihypertensive Agents - therapeutic use Antihypertensives Antipsychotic Agents - therapeutic use Antipsychotics Attention deficit hyperactivity disorder California Cardiovascular Agents - therapeutic use Conflict of Interest Conflicts of interest Data processing Diabetes Diabetes mellitus Drug development Drug Industry Drug Prescriptions - statistics & numerical data Drugs Exposure Gastroesophageal reflux Health care facilities Health facilities Humans Hyperactivity Hypnotics Hypnotics and Sedatives - therapeutic use Hypoglycemic Agents - therapeutic use Illinois Insomnia Interprofessional Relations Intervention Market shares Markets Massachusetts Medical personnel New York Organizational Policy Original Investigation Pennsylvania Pharmaceutical industry Pharmaceuticals Physicians Physicians - statistics & numerical data Policy implementation Prescription drugs Prescription Drugs - therapeutic use Prescriptions Regression Analysis Salespeople Sleep Sleep disorders |
| Title | Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing |
| URI | http://dx.doi.org/10.1001/jama.2017.4039 https://www.ncbi.nlm.nih.gov/pubmed/28464141 https://www.proquest.com/docview/1897789154 https://www.proquest.com/docview/1894917529 https://pubmed.ncbi.nlm.nih.gov/PMC5815013 |
| Volume | 317 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_rCeKL6PlVPSWC4MPSo2nSJn08vzgVReEO7q00TdYTpCtr98W_wz_YyWfTvRNOX8rSpm02v-lkZjL5DULPq5UCnCnNYfIpwEFpilwKzXINUwHv645SZRNkP9XHp-z9WXW2WPxOspa2ozzsf126r-R_UIVzgKvZJfsPyMaHwgn4DfjCERCG45UwTsZ2-dInXMWE97AEY-K3erP8fD4LXr-2qaMmTmCZgcFfdvsGQqDD5maARpFhagsGLCjpZUgGSWgnkh0q0-rPLvaW4HHjC4C9m-TyyCkc8IFh6FQM-phCnNDrMY3yJ-kIa7fXyNYrT4MXMCGaVME0npnQmUaFTN1uziB5PNGvhLsCPxcUf1JwwLznkBWOI2nOsL0z88V8RMfdDJ4Q3N-a-1tz_zV0vQTnw9TF-PBFJKRkcybWQAU6cVn596fkvcHgueDF7CbjJtbNyW10y7sl-MjJ2B200MM-uvHRJ17cRV8TKLEXNRxEDXu8sRM1PBc1HEUNB1HDIGo4ihpORO0eOn375uTVce5rdOQdo3zMlSzLruOk56uKdHXHpeRiZRJ8WaN0xXoFE4pWilU9ERqcWd5w3TGlG1nzmih6H-0N60E_RJj2XJd1o0BVQAMqpRKlKGQhVV-uwGzK0L6B54djYWlLMNzrgmcoD8Pb9p7W3lRX-d5eDmqGXsT24VF_a3kQ0Gr99_SzJQIcJtGA45GhZ_EyqGSzztYNer21bVgDZrnp8gMH7tRrsPcZYSRDfAZ7bGDo3udXhm_nlva9EuC8Efroyn_gMbo5fXMHaG_cbPUTMKFH-dRK9B8xz8jE |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+Between+Academic+Medical+Center+Pharmaceutical+Detailing+Policies+and+Physician+Prescribing&rft.jtitle=JAMA+%3A+the+journal+of+the+American+Medical+Association&rft.au=Larkin%2C+Ian&rft.au=Ang%2C+Desmond&rft.au=Steinhart%2C+Jonathan&rft.au=Chao%2C+Matthew&rft.date=2017-05-02&rft.issn=0098-7484&rft.volume=317&rft.issue=17&rft.spage=1785&rft_id=info:doi/10.1001%2Fjama.2017.4039&rft.externalDBID=n%2Fa&rft.externalDocID=10_1001_jama_2017_4039 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0098-7484&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0098-7484&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0098-7484&client=summon |